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The prevalence and degree of antibacterial resistance in common respiratory pathogens are increasing worldwide. 
The health impact of resistance is not yet fully understood. However, once the impact of resistance becomes 
measurable, it may be too late to apply interventions to reduce resistance levels and regain previous quality and cost 
of care. We should address resistance now, before patient care is irreversibly compromised. The association between 
antibiotic consumption and the prevalence of resistance is widely assumed. However, evidence suggests that there is 
a more complex, multifactorial relationship between antibiotic use and resistance. It is also assumed that there is an 
adaptive fitness cost for bacterial resistance mutations. However, in some cases, bacteria are able to acquire 
‘compensatory genes’ negating any negative impact of resistance mutations. Mathematical modeling indicates that 
the timescale for the emergence of resistance is typically shorter than the decay time following a decline in antibiotic 
consumption. Against this background, a general principle is proposed: to maximize patient outcome whilst 
minimizing the potential for selection and spread of resistance. This may be achieved through the use of agents that 
fulfill defined pharmacodynamic and pharmacokinetic parameters and elicit rapid eradication of the bacterial 
population, including emerging resistant mutants, from the site of infection. The choice of agent may not be the 
same in all regions, as selection will depend on local resistance patterns and disease etiology; however, the 
application of this principle may help to preserve the benefits of antibiotic therapy. 
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resistance; transient hypermutation. 
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Introduction 
The high prevalence of antibiotic resistance has now 
become a global public health concern (1). Many species 
and strains of bacteria that are pathogenic to humans have 
developed resistance to both well-established and newer 
antibiotics. Multiply-resistant organisms (e.g. drug-resis- 
tant Streptococcus pneurnoniue, DRSP) give particular 
cause for concern. These bacteria are responsible for 
increased numbers of infections in both hospitals and the 
community (see Garau, ‘Clinical failures: the tip of the 
iceberg?‘, this issue). 
Resistant pathogens compromise the bacteriological and 
clinical efficacy of common antibiotic regimens (see Garau, 
‘Clinicalfailures: the tip of the iceberg?, this issue). As the 
prevalence and degree of resistance increases, the choice of 
effective antibiotic therapy becomes more restricted. The 
failure of antibiotic therapy also has cost implications. For 
example, a recent study found that when the choice of 
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antibiotic therapy matched the susceptibility results for an 
episode of lower respiratory tract infection, the mean cost 
of therapy was almost US$ 6000 lower than when therapy 
did not match the pathogen susceptibility (P= 0.02) (2). 
With few exceptions, the introduction of an antibiotic is 
followed by an increase in the prevalence of resistance. In 
general, resistance tends to be more prevalent in closed 
environments (e.g. daycare centers, intensive care units) and 
in countries with high antibiotic exposure. Antibiotic 
resistance can emerge following a spontaneous chromoso- 
ma1 mutation or through the introduction of foreign genetic 
material, e.g. through plasmids. Under selective antibiotic 
pressure, isolates carrying resistance genes may persist, 
leading to continued carriage and spread of the resistant 
strains throughout the community. Examples showing 
reversibility of antibiotic resistance in the community by 
modifying the volume and patterns of antibiotic usage are 
scarce, and bacteria may overcome the biological cost of 
resistance by molecular adaptation (3). 
This paper will address three specific issues-first, the 
quantitative and temporal relationships between antibiotic 
use and resistance, second, whether or not resistance is 
reversible and, third, whether the rate at which resistance 
develops can be reduced through improved pharmacologi- 
cal strategies. 
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Antibiotic use and resistance- 
quantitative and temporal 
relationships 
At present, it is difficult to establish a precise quantitative 
relationship between the frequency of resistance to a 
defined antibiotic and the volume of drug use, because of 
the scarcity of longitudinal studies which record resistance 
and drug use patterns and the often multifactorial aspect of 
emergence of resistance (4). However, mathematical models 
have been shown to be useful tools in examining the effects 
of various patterns of antibiotic drug use at the population 
level. Models are based on available data and assume that 
the major selective pressure driving changes in the 
frequency of resistance is the volume of drug use. Such 
models indicate that the higher the level of antibiotic 
consumption, the faster the emergence of resistance (4) 
(Fig. 1). 
Despite the apparently clear correlation predicted from 
mathematical modeling, there is no one simple relationship 
between antibiotic consumption and bacterial resistance in 
nature. Factors influencing this relationship include vari- 
able epidemiology, regional differences, co-selection (where 
multiple resistance is present an antibiotic of one class can 
increase resistance to an antibiotic of another class), cross- 
infection, clonal spread as well as differences in the 
pharmacokinetics/pharmacodynamics (PK/PD) of antibio- 
tics and their ecological impact on the normal flora. 
For example, the impact of co-selection on antibiotic 
resistance was described in a study conducted in Iceland 
involving 9 19 children ( < 7 years of age) (5). In this study, a 
high prevalence of resistant pneumococci was found, most 
of which (80%) were multiresistant (5). Analysis indicated 
that the odds ratio for co-trimoxazole or erythromycin 
being associated with penicillin-resistant pneumococcal 
(PRP) carriage was twice that for fi-lactams in association 
with three or more courses of antibiotic treatment. Thus, in 
this case, penicillin resistance was more likely to be related 
to the use of co-trimoxazole and erythromycin than to the 
use of /I-lactams (5). 
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FIG. 1. Correlation between antibiotic consumption and 
resistance derived from a mathematical model. DDDs: 
defined daily doses. Reproduced with permission (4). 
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Is antibiotic resistance reversible? 
HOW DO BACTERIA RESPOND TO 
ANTIBIOTICS? 
521 
Exposure to an antibiotic acts as a physiological ‘stress’ on 
bacteria. However, they possess a range of adaptive 
mechanisms to ensure their continued survival. The rate 
of spontaneous mutation or the rate of transfer of genetic 
material between organisms may increase. For example, 
Oliver et al. described transient hypermutation in Pseudo- 
monas aeruginosa under environmental stress (6). The 
investigators determined the spontaneous mutation rate in 
128 P. aevuginosa isolates from 30 patients with cystic 
fibrosis (CF). Mutator strains were found in 36% of 
patients. These strains persisted for years in most patients, 
and had a frequency of antibiotic resistance roughly twice 
that of non-mutator isolates (6). Hypermutation is a state in 
which bacteria mutate at a much more rapid rate than 
normal due to alterations in the DNA mis-match repair 
process. It is thought that this process increases the 
adaptive diversity of the bacterial population, presumably 
allowing them to overcome rapidly changing conditions or 
exploit newly emerging environmental niches. The lungs of 
CF patients are chronically infected with P. aeruginosa. 
These organisms must continually adapt to limitations in 
specific growth factors, dehydration, deteriorating lung 
tissue etc., as well as to frequently changing and prolonged 
(over a period of years) antibiotic therapy (6). 
ADAPTIVE COSTS OF ANTIBIOTIC 
RESISTANCE 
It is widely believed that the development of antibiotic 
resistance imposes some biological (fitness) cost on the 
bacterium. Data from in vitro studies indicate that 
resistance encoded by chromosomal mutations, i.e. primar- 
ily by the modification of drug target molecules, imposes 
some cost to fitness. However, mutants with no measurable 
adaptive cost have also been observed (3). 
If the acquisition of chromosomal resistance does impose 
an adaptive cost, e.g. a slower growth rate, there are two 
possibilities for addressing this deficit in fitness: (i) by 
reverting to the susceptible state (‘true reversion’-very 
rare) or (ii) through the acquisition of compensatory 
(intragenic or extragenic) mutations (Table 1) (3). For 
example, the fitness cost of the point mutation conferring 
resistance in Salmonella typhimurium can be compensated 
for by intragenic or extragenic mutations that have no 
impact on the resistance status of this pathogen, 
Resistant mutants that cannot overcome any fitness loss 
by reversion or compensatory mutation will presumably be 
at a competitive disadvantage compared with susceptible 
isolates once the antibiotic pressure has been removed. In 
this situation, the prevalence of resistance would be 
expected to fall. However, mathematical models indicate 
that the emergence of resistance is typically far more rapid 
than the decline (4) (Fig. 2). 
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TABLE 1. Compensatory evolution and amelioration of fitness losses. Adapted from (3) 
Pathogen Resistance mutation Compensatory mutation Resistance maintained 
Salmonella typhimurium 
Staphylococcus aureus 
Escherichia coli 
Mycobacterium tuberculosis 
rpsL (streptomycin) 
rpsL (streptomycin) 
gyrA (nalidixic acid) 
rpoB (rifampicin) 
fusA (fusidic acid) 
fusA (fusidic acid) 
jiis (fusidic acid) 
rpsL (streptomycin) 
rpoB (rifampicin) 
katG (isoniazid) 
Intragenic, rpsL 
Extragenic, rpsD/E 
Intragenic, gyrA 
Intragenic, rpoB 
True reversion, fusA 
Intragenic, fusA 
Intragenic, fus 
Extragenic, upsDIE 
Intragenic, rpoB 
Extragenic, ahpC 
Yes 
Yes 
Yes 
Yes 
No 
Often 
Yes/no 
Yes 
Yes 
Yes 
15 
0 
: 25% : 50% :75% 
‘15 25 36 46 55 65 
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FIG. 2. Emergence of resistance is typically more rapid 
than decline. -: time taken for resistance to increase from 
1 to 10%; - - - : time taken for resistance to decrease 
following reductions in antibiotic consumption of 25, 50, 
75 and 100%; DDDs: defined daily doses. Reproduced 
with permission (4). 
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FIG. 3. Reduction in the frequency of erythromycin 
resistance among group A streptococcal isolates in 
Finland, following nationwide recommendations to 
restrict the use of macrolide antibiotics for outpatients 
with skin or respiratory tract infections. Reproduced with 
permission (8). 
EVIDENCE OF REVERSAL OF RESISTANCE 
There is some evidence that resistance can be reduced by 
reducing antibiotic selective pressure in the hospital 
environment. For example, interventions in a Greek 
hospital attempted to reduce the high level (around 30%) 
of quinolone resistance that was observed in Gram-negative 
pathogens (Pseudomonas aeruginosa, Klebsiella spp. and 
Proteus mirabilis) (7). Between the beginning of 1995 and 
the end of 1996, there was a six-fold reduction in quinolone 
use and a significant fall in the prevalence of resistance 
among these pathogens-P. aeruginosa (34% to IS%), 
Klebsiella (26% to 6%) and P. mirabilis (30% to 16%) (7). 
There are only scarce reports of resistance reversal in the 
community-one from Finland (8) and another from 
Iceland (9). In one report from Finland, during the early 
199Os, there was an increase in erythromycin resistance 
among group A streptococci (8). In order to address this 
concern, nationwide recommendations were issued for a 
reduction in the use of erythromycin for outpatients with 
respiratory tract (RTIs) or skin infections. From 1991 to 
1992, the consumption of macrolides decreased from 2.40 
defined daily doses (DDD) per 1000 inhabitants to 1.38 
(P = 0.007), with a concomitant steady decrease in the 
frequency of erythromycin resistance among group A 
streptococci, from 16.5% in 1992 to 8.6% in 1996 (Fig. 3) 
(8). Another report, from Iceland, comes from a study 
published in 1998, which evaluated the impact of reducing 
antibiotic consumption on PRP carriage (9). The incidence 
of penicillin-non-susceptible pneumococci (PNSP) had been 
increasing in Iceland since the late 198Os, and a policy was 
implemented to reduce antimicrobial use, particularly for 
upper respiratory tract infection in children. The particular 
risk associated with trimethoprim-sulfamethoxazole use 
was emphasized. From 1990, the overall national antibiotic 
consumption was reduced by lo%, though the consump- 
tion of trimethoprim-sulfamethoxazole and erythromycin 
were reduced by 30%. Although the incidence of PNSP 
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reached a peak in 1993 (19-S%), it fell, thereafter, reaching 
just 12.9% in 1997 (9). Thus, for these two examples, a 
reduction in consumption of an individual antibiotic or 
antibiotic class seemed to result in a reduction in the 
frequency of resistance. However, spontaneous disappear- 
ance of resistance clone(s) due to acquired herd immunity 
after antibiotic exposure may also be a partial explanation. 
For example, in a study by Leach et al. (lo), there was a 
reduction in resistance to azithromycin over time that 
coincided with the average time that pneumococci clones 
are carried in the nasopharynx. Similarly, in a study by 
Arason et al. (5), the impact of previous antibiotic exposure 
on resistance decreased after 2 months, probably reflecting 
immunological eradication of the carriage of resistant 
clones. 
In southern Sweden, there has also been concern over the 
high prevalence of resistant pneumococci, which increased 
to 15% during the early 1990s though the corresponding 
figures for the rest of Sweden remained at lower levels (11). 
A national expert committee was formed, and discussions 
soon focused on the spread of resistant pneumococci in 
small children, especially those attending daycare centers. A 
restriction on antibiotic consumption was imposed while, 
alongside this policy, a measure was initiated where 
children with positive cultures for PNSP were not allowed 
to attend daycare centers until they had two consecutive 
negative tests. Parents staying at home with these children 
were reimbursed by the social security system. Since then, 
there has been a substantial reduction in the use of 
outpatient antibiotic use, particularly macrolides and 
broad-spectrum penicillins. As yet, this dual strategy has 
not led to a significant reduction in PNSP-the prevalence 
remains at around lo%-though there is a trend towards 
fewer index cases, i.e. individuals first identified with PNSP. 
The effect of these measures on contact cases (close contacts 
of the index case) are not yet clear, though are likely to 
become apparent as the study continues (11). 
These studies illustrate that, though in many cases 
resistance may well be reversible, once detected, there is a 
need for early action. In addition, strategies to bring about 
a reversal of resistance, particularly in the community, are 
likely to be multi-faceted, extensive, protracted and 
potentially costly. 
Can improved pharmacological 
strategies limit the rate at which 
resistance develops? 
One way to reduce the rate of development of resistance is 
to ensure that the dose and activity of an antibiotic will 
minimize the risk for selection of resistant mutants. Early 
use of highly active and rapidly bactericidal antibiotics will 
reduce the ancestor bacterial population, decrease the 
possibility of emerging resistant strains and avoid the 
selection of low-level mutants which may be considered as 
‘stepping stones’ for high level resistance. The use of PK/ 
PD parameters in defining optimal antibiotic therapy is 
discussed by Craig, ‘Re-evaluating curvent antibiotic ther- 
apy’, this issue. 
SUB-OPTIMAL ANTIBIOTIC REGIMENS 
AND RESISTANCE-CAUSE AND EFFECT? 
Several studies have described a possible relationship 
between the use of sub-optimal antibiotic doses and the 
emergence of resistance in S. pneumoniae. Baquero (12) 
described that during the early 1990s in France, there was a 
shift from the use of oral aminopenicillins towards oral 
cephalosporins for the treatment of RTIs. Correspondingly, 
there was an increase in penicillin resistance in 5’. 
pneumoniae-a key respiratory pathogen (Fig. 4). It is 
possible to explain this shift in the resistance pattern in 
France by the differences in PKjPD parameters between the 
two drug classes. For cephalosporins, serum concentrations 
above MIC for at least 40% of the dosing interval is 
thought to be required for effective antimicrobial treatment. 
However, the serum concentrations of many of the oral 
cephalosporins being used increasingly in France at this 
time fail to meet this parameter for S. pneumoniae with 
reduced penicillin susceptibility. Use of these agents would, 
therefore, be expected to result in a poor level of bacterial 
eradication and the persistence and spread of resistant 
strains (12). 
Another example is the correlation observed between the 
use of new, long-acting macrolides (e.g. azithromycin and 
clarithromycin) and the emergence of macrolide resistance 
in S. pneumoniae (13) (Fig. 5). The long half-lives of these 
agents, combined with serum concentrations which do not 
exceed the MIC throughout the dosing interval, may be 
driving the selection of macrolide resistance in S. pneumo- 
niae. There was no correlation observed between the 
increase in macrolide resistance and the use of older, 
short-acting macrolides, such as erythromycin (13). Re- 
cently, a similar correlation between the use of azithro- 
mycin and emergence of macrolide/penicillin-resistant 
S. pneumoniae has been reported from Denmark (14). 
30 , .g 
a 
FIG. 4. Relationship between a shift in the use of oral 
aminopenicillins and oral cephalosporins and the 
emergence of penicillin resistance in S. pneumoniae. n : 
penicillin resistance in S. pneumoniae; 0: ratio of 
aminopenicillins: cephalosporins per 1000 inhabitants in 
France. Reproduced with permission (12). 
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FIG. 5. Correlation between prescribing of short-acting 
and long-acting macrolides and macrolide resistance in 
S. pneumoniae. n , - - -: short-acting; 0, -: long- 
acting. Reproduced with permission (13). 
Treatment duration is another factor to consider, though 
it is not yet clear how important this is in relation to the 
development of resistance, and there is little clinical 
information on the subject. One clinical study, carried out 
in a group of French children, indicated that the 
nasopharyngeal carriage of penicillin-resistant S. pneumo- 
niae was associated with low dose (lower than clinically 
recommended) and long duration p-lactam therapy (>5 
days) (15). Although this study was small, it does suggest 
that there is some connection between treatment duration 
and resistance. Logically, shorter treatment times should be 
advantageous. However, it is also likely that some 
bacteriological efficacy would be lost if treatment times 
were shortened. Further studies are required to define the 
point at which this optimal balance is achieved. 
Improved pharmacological strategies may, indeed, help 
to limit the rate at which resistance develops. Such 
strategies will, however, require the use of evidence-based 
treatment guidelines derived from clinical trial data. One of 
the limiting factors in the development of such guidelines, 
however, is the way in which clinical trials are currently 
designed and conducted. Vital data are often either not 
reported or not collected, for example, efficacy rates versus 
placebo, optimal dose regimens, bacteriological eradication 
rates, the ecological impact of the antibiotic and the 
selection of resistance in normal flora. 
Conclusion-have we reached the 
point of no return? 
There is no certainty that the current extent of resistance 
can be reversed-the point of no return may already have 
been reached for certain antibiotic-bacterial combinations. 
Antibiotic resistance tends to go unnoticed and unmeasured 
for long periods of time-at least, as long as there is no 
clinical impact. Once resistance does begin to affect clinical 
efficacy-as it has now (see Garau, ‘Clinical failures: the tip 
of the iceberg?, this issue&then it may, indeed, be already 
too late to implement measures which may make a 
difference. 
What is clear is that to limit the further development and 
spread of resistance there must be judicious use of 
antibiotics, with reductions in unnecessary and inappropri- 
ate use. Antibiotic use must be ‘appropriate’, that is limited 
to appropriate circumstances, and optimal dose regimens 
should be defined according to specific PKjPD principles, 
particularly for new agents. Agents with the greatest 
potential for rapid eradication of susceptible bacteria and 
more resistant sub-populations should be chosen as first- 
line therapy. Agents to be avoided are those with sustained, 
low concentrations at the site of infection and those that 
have the greatest effect on the normal flora. Whilst the 
choice of antibiotic may not be the same in all regions and 
will depend on local resistance patterns and disease 
etiology, the application of these principles may help to 
preserve the benefits of antibiotic therapy through max- 
imization of clinical outcomes and minimizing the potential 
for selection and spread of resistance. 
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